Biotech Values

[RockRat]

ARDX program halt: saves a little money for tenapranor launch :>) They burned 70 million over the last year, at a time when clinical expenses were probably coming down, and launch expenses hadn't really started. In other words, I expect their $130 million isn't going to get them to profitability (and that's rosily assuming tenapranor can compete, a very open question). I still expect a financing soon, within six months, and more likely in the next two or three.

Regards, RockRat